Vivek Ramaswamy's 'vant' brainchildren keep bearing fruit with Urovant's FDA nod for incontinence med vibegron
Christmas has come early for Urovant Sciences as the former Vivek Ramaswamy outfit scored an FDA approval for its lead program.
The biotech’s overactive bladder candidate vibegron will be the newest drug to hit the market, the agency said Wednesday, giving Urovant its first approved product. Vibegron, a beta-3 agonist that’s taken as a once-daily pill, will be sold as Gemtesa. The drug is likely to launch in early 2021, CEO James Robinson has previously said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,500+ biopharma pros reading Endpoints daily — and it's free.